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Abstract: The early work on neuropeptide-monoamine receptor-receptor interactions in the Central Nervous System 
gave the first indications of the existence of G protein-coupled receptors (GPCRs) heteroreceptor complexes and the 
GPCR field began to expand from monomers into heteromers and higher order heteromers, including also GPCR-ion 
channel, Receptor Tyrosine Kinases (RTK)-GPCR and Receptor activity-modifying proteins-GPCR heteroreceptor 
complexes. The existence of heteroreceptor complexes with allosteric receptor-receptor interactions increases the 
diversity of receptor function including recognition, trafficking and signalling. We have proposed the molecular 
phenomenon of receptor-receptor interactions as a good way to understand of how brain function can increase through 
molecular integration of signals. An alteration in specific receptor-receptor interactions or their balance/equilibrium (with 
the corresponding monomers-homomers) are indeed considered to have a role in the pathogenic mechanisms that lead 
to various diseases, including drug addiction, depression, Parkinson's disease and schizophrenia. Therefore, targeting 
protomer-protomer interactions in heteroreceptor complexes or the balance with their corresponding homoreceptor 
complexes in discrete brain regions may become an important field for developing novel drugs, including heterobivalent 
drugs and optimal types of combined treatments. Increasing our understanding of molecular integration of signals via 
allosteric receptor-receptor interactions in the heteroreceptor complexes will have a major impact on the molecular 
medicine, leading to novel strategies for drug discovery and treatment of diseases. 
Keywords: G protein-coupled receptors, Dimerization, Oligomerization, Homdimer, Heterodimer, Homoreceptor 
complexes, Heteroreceptor complexes, Receptor-receptor interaction, Networks, Dopamine receptor, Serotonin 
receptor. 
INTRODUCTION 
The modulation of the binding characteristics, 
especially the affinity, of the monoamine receptors in a 
receptor subtype specific way by neuropeptides was 
tested in 1980-1981 and it opened the door to 
hypothesized the existence of an intramembrane 
receptor-receptor interactions phenomenon [1-10]. 
Thus, it was postulated that direct interactions may 
exist in addition to indirect actions via receptor 
phosphorylation, changes in the membrane potential or 
the involvement of adapter proteins [11-15]. Later on in 
1998-1999, it was demonstrated that two non-
functional GPCR receptors, GABAB1 and GABAB2 
protomers, can assemble in a signalling heterodimer at 
the cell surface, confirming definitely the phenomenon 
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of GPCR heteromerization [16, 17]. In addition, 
biophysical approaches (i.e. Fluorescence and 
Bioluminescence Resonance Energy Transfer 
methods, FRET and BRET respectively) provided the 
evidence needed to demonstrate the existence of 
GPCR heteroreceptor complexes in living cells [18-23]. 
In recent decades, a series of relevant contributions 
have demonstrated the importance of 
heterodimerization processes within the GPCR 
superfamily [18-20, 24-41].  
We have suggested that allosteric mechanisms, 
which make possible the integrative intermolecular 
activity, take place via the interface interaction in the 
homoreceptor or heteroreceptor complexes. As to the 
protomers interface we have observed a high energy 
strength double arginine-phosphate electrostatic 
interaction in the adenosine A2AR-dopamine D2R 
heteroreceptor complexes representing a hot spot in 
the protomer interface [41, 42]. The allosteric 
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mechanisms in the heteroreceptor complexes open up 
the door for a marked rise of the diversity of the 
GPCRs, e.g, their recognition, trafficking and signalling 
[20, 21, 39, 40, 43-48]. This is possible through 
modulation of the orthosteric/allosteric binding sites of 
the adjacent protomer, its G protein activation, its 
selectivity for scaffold protein recruitment and among 
others switching from G proteins to -arrestin 2 [43, 46, 
49-55]. The concept of moonlighting protein is 
employed to describe "multifunctional proteins in which 
several functions can be found in a single strand of 
amino acids unrelated to splicing, posttranslational 
changes etc" [56-58]. Moonlighting of GPCR 
heteroreceptor complexes may be brought about by the 
allosteric receptor-receptor interactions changing the 
function of the protomers of the heteroreceptor 
complexes [55, 59, 60]. The current state of the art in 
the brain dopamine D2 like, adenosine A2AR and 
serotonin 5-HT1AR heteroreceptor complexes will be 
described as well as some relevant methods/- 
techniques that could allow also the understanding of 
the balance between corresponding homo-and 
heteroreceptor complexes [61-63].  
THE OVERALL ARCHITECTURE OF THE GPCR-
GPCR HETERORECEPTOR COMPLEXES 
The entire number of demonstrated GPCR 
heteroreceptor complexes was linked together and 
represented as a GPCR heterodimer network (GPCR-
HetNet: http: //www.gpcr-hetnet.com/ [64]. In this study 
static/non-dynamical human GPCR data were manually 
collected with a total of 187 different nodes/protomers 
(until August 2014) derived from 537 GPCR-GPCR 
edges/interactions studies in databases and literature. 
These data were then integrated into a scale graph, 
which was named the GPCR heterodimer network 
(GPCR-HetNet), where the nodes are the 
heteroreceptor complexes protomers and the edges 
are the relationships or interactions between them. The 
analysis of the GPCR-HetNet indicate a scale free 
model in which only a few protomers dominate the 
connectivity and sustain the network together. Two hub 
criteria show that the growth hormone secretagogue 
receptor type 1, dopamine D2 receptor, the mu-type 
opioid receptor, the beta-2 adrenergic receptor, the 
secretin receptor, Cannabinoid receptor 1 and the 
delta-type opioid receptor are the hubs in the network. 
Other very well connected protomers are also observed 
and identified in this work, as well as the potential of 
existence of novel receptor-receptor interactions or the 
formation of higher order heteroreceptor complexes. In 
this study the overall architecture of the GPCR-GPCR 
heteroreceptor complexes is for the first time 
presented, which provides important insight into 
receptor-receptor interaction connectivity, topology and 
organization. And may contribute to a better 
understanding of the complexity of GPCR 
heteroreceptor systems [64]. 
Although in this work the homomer information was 
excluded, we have emphasized the facts that a high 
percent of the total protomers described exists as 
homomers. [64]. In lines with this evidence, it must be 
point out that by means of fluorescence correlation 
spectroscopy it has been demonstrated that biogenic 
amine receptors, freely diffusing within the plasma 
membrane, are predominantly homodimers and not 
monomers [65].  
The study of receptor-receptor interaction 
connectivity (intrafamily and interfamily) has also 
shown a significant prevalence of intrafamily versus 
interfamily connections [64]. We have claimed that one 
mechanism which could explain the marked dominance 
of intrafamily versus interfamily connections could be a 
favourable coevolution of the receptor-receptor 
interface interaction inside each subfamily. One 
characteristic of GPCRs subfamilies is the high 
sequence homologies/similarities of its member 
receptors and their reduced sequence homologies with 
other GPCR subfamilies [66]. For instance, Class B 
superfamily (Secretin-like), is suggested to have 
emerged from a single ancestral gene via gene 
duplication [67, 68]. As a result it shows a high 
sequence homology between its members [68]. 
Furthermore, it was demonstrated that homologues 
receptors belonging to the same subfamily can share 
similar interaction interfaces where their exposed 
residues can be either intermixed or run in parallel to 
one another [69]. Also, domain swapping phenomena 
can occur via their conserved domains/motifs, as have 
been shown for some GPCR heteroreceptor complexes 
[29, 30, 70]. Another reason could be the particular cell 
and tissue expression pattern of some GPCR [43, 47, 
71-75]. Some receptor classes, for instance TAS2R 
bitter taste receptors, are expressed in more restricted 
types of cells, tissues or organ than other receptors 
that are more widely expressed. Therefore, their 
members have a lower chance of encounters and 
interactions. Furthermore, a need for more 
experimental data who focus on the study of GPCR 
interfamily heteroreceptor complexes should be 
considered. So far, only a few groups have focused 
their efforts on the study of the specificity of GPCR 
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heteromer interactions, and we expect in a near future 
a more wide-spread existence of cross-family 
heterodimerization or a definite experimental 
confirmation of a lower number of inter family 
interactions, as shown in the analysis of GPCR-HetNet 
(http: //www.gpcr-hetnet.com/). 
It must be highlighted that the GPCR HetNet is so 
far the first and the only work that took into 
consideration not only a topological and architectural 
perspective of GPCR receptor-receptor interactions, 
but also the relevance of the specificities of the GPCR 
heteroreceptor complexes. In this database is 
presented in addition to the GPCR-GPCR interactions, 
that have been demonstrated experimentally by means 
of biophysical (BRET, FRET, FCCS) and biochemical 
(coimmunoprecipitation, in situ Proximity Ligation 
Assay (in situ PLA), and radioligand binding) methods, 
also their specificities and promiscuity. We have 
developed two networks, one represents the so called 
"positive receptor-receptor interaction" or GPCR 
HetNet and another one the GPCR Non-HetNet (see 
as well, http: //www.gpcr-hetnet.com/), which 
represents the experimentally demonstrated non-
interacting GPCR protomers. Relevant facts could be 
extrapolated from the comparison between both 
networks, like for example, the interaction pattern of the 
alpha-1D-adrenergic receptor, which shows a low level 
of connectivity in the HetNet but a high level of non-
interactions in the Non-HetNet.  
DOPAMINE D2-LIKE AND ADENOSINE A2A 
HETERORECEPTOR COMPLEXES 
There exists evidence for the presence of A2AR-
D2R heteroreceptor complexes not only in cell lines 
[41, 42, 63] but also in the rat striatum using the in situ 
PLA [71, 76] as well as indications for the existence of 
striatal A2AR-D3R and A2AR-D4R heteroreceptor 
complexes. Antagonistic A2AR-D2R interactions exist 
in the striatal A2AR-D2R heteroreceptor complexes 
reducing D2R recognition and signalling which has led 
to a novel understanding of the molecular bases behind 
the pathophysiology of drug addiction, Parkinson's 
diseases (PD) and L-DOPA-induced dyskinesias of 
high relevance for their treatments [52, 55, 63, 77-79]. 
Based on this, A2AR antagonists are being proposed in 
the symptomatic treatment of PD [52]. In line with these 
results A2AR agonists have been shown to have 
atypical antipsychotic actions and to possess anti-
cocaine actions in development and reinstatement of 
cocaine self-administration [77]. Also antagonistic 
CB1R-D2R interactions likely exist in striatal CB1R-
D2R heteromers leading to a reduced D2R signalling 
and counteraction of D2R-induced hyperlocomotion 
[80, 81]. Higher order heteromers may also be found 
since there are indications for the presence of striatal 
A2AR-CB1R-D2R trimers and A2AR-D2R-mGlu5R 
trimers with integrative receptor-receptor interactions 
modulating the activity of the striato-pallidal GABA 
neurons [82, 83]. In the latter trimer the A2AR and 
mGlu5R synergize to counteract the D2R signalling to 
allow firing of the striato-pallidal GABA neurons without 
being restrained by the inhibitory D2R signalling. In this 
way these receptors can potentially override a 
pathologically increased D2R signalling present in 
schizophrenia. In the former trimer the antagonistic 
CB1R-D2R interaction activated by endocannabinoids 
removes the D2 brake on the A2AR signalling to the 
adenylyl cyclase contributing to a markedly increased 
activity of the striato-pallidal GABA neurons [81]. The 
A2AR-CB1R-D2R trimer may function mainly as an 
inhibitory feedback mechanism to reduce an 
exaggerated and prolonged activation of D2R removing 
an excessive silencing of the striato-pallidal GABA 
neurons. Thus, these two types of GPCR trimers are 
also potential novel drug targets for treatment of PD, 
schizophrenia and cocaine addiction. 
SEROTONIN 5-HT1A HETERORECEPTOR COM- 
PLEXES 
As to the 5-HT1AR heteroreceptor complexes 
evidence exists that Galanin receptor1 (GalR1) 
modulates 5-HT1AR signalling via heterodimerization 
in cellular models [21]. These results amplify the 
indications that there exist brain GalR1-5-HT1AR 
heteromers in which the previously observed 
antagonistic galaninR-5-HT1A receptor-receptor 
interactions in the limbic system take place [84]. 
Targeting different types GalR-5-HT1AR heteromers 
may be a novel therapeutic strategy for treatment of 
depression [53, 72, 84]. Targeting the recently 
discovered FGFR1-5-HT1AR heteroreceptor 
complexes of the hippocampus may be another 
therapeutic approach in depression in view of their 
enhancement of hippocampal plasticity [75, 85]. 
Combined acute and repeated intracerebrocentricular 
treatment with FGF2 and 8-OH-DPAT have shown 
evidence as significant antidepressant in the forced 
swim test [75]. These heteroreceptor complexes were 
also observed in midbrain 5-HT neurons of the rat [73]. 
The 5-HT1A autoreceptor protomer upon agonist 
activation produced an allosteric enhancement of the 
FGFR1 signaling in the midbrain raphe 5-HT nerve 
cells leading to increases in their neuroplasticity and 
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trophism. Thus, the 5-HT1A autoreceptor in this 
heteroreceptor complex can also have a trophic role of 
importance for depression and its treatment in addition 
to its key role in reducing the firing of the ascending 
midbrain 5-HT neurons. 
New findings have shown that combine treatment 
with 8-OH-DPAT and FGF2 but not treatment with the 
5-HT1A agonist alone significantly increases the 
BRETmax values and markedly reduces the BRET50 
values on the 5HT1A homodimerization in cellular 
models co-expressing 5-HT1A and FGFR1 [86]. FGF2 
produces a rapid rise in FGFR1 homodimerization 
which, to certain extent, declined over a 10 min period. 
Combine treatment with 8-OH-DPAT blocked this 
decline in FGFR1 homodimerization. Also, it was 
observed that FGF2 only produced a small rise in the 
BRET
2
 signal from the 5-HT1A--arrestin2 complex 
which was additive to the significant effect of 8-OH-
DPAT alone. All together, these results have shown a 
dynamic modulation of the allosteric receptor-receptor 
interactions in the FGFR1-5-HT1A heteroreceptor 
complexes with regard to their impact on 5-HT1AR and 
FGFR1 homodimerization [86]. 
METHODS FOR STUDYING GPCR RECEPTOR-
RECEPTOR INTERACTIONS  
In the last years, interactions involving GPCRs were 
demonstrated through diverse biophysical (FRET, 
BRET, BiFC) and biochemical or microscopy-based 
procedures (e.g. coimmunolocalization, coimmuno- 
precipitation, radioligand binding, co-internalization 
analysis) including methods that assess receptor-
receptor interactions [22, 23, 85, 87, 88]. Each 
methods or tools employed has gave a precise and 
valuable information which has been considered with 
caution to avoid undesirable drawbacks. Some 
controversy regarding some approaches have also 
emerged [89, 90]. Nevertheless, when these methods 
are properly assessed it is possible to demonstrate 
elegantly the direct interactions between GPCRs and 
as well as their dynamics. [91-93]. 
Novel technologies to study receptor heteroreceptor 
complexes and their receptor-receptor interactions 
have recently been developed such as real-time FRET 
experiments in living cells [94], dual-colour 
fluorescence cross-correlation spectroscopy (FCCS) 
[65] and mass spectrometry of phosphorylation 
fingerprints from receptor protomers of receptor 
heteromer and homomers [95]. A new dimension in the 
GPCR heteromer field was also introduced in 2010 by 
the evidence obtained, in cellular models first [48] and 
in brain tissue later [43, 46, 47, 72-76, 85], of the 
existence of GPCR heteroreceptor complexes by 
means of the in situ PLA. This method offers the 
advantages of the analysis of any receptor-receptor 
interactions for which suitable antibodies are available 
without using genetic constructs. As with any method 
there are limitations, for instance, in situ PLA could only 
be used in ex vivo fixed material. The method strongly 
relies on the quality of the antibodies used, and we 
must take into account parameters such as antibody 
concentration, epitopes targeted by the antibodies, 
fixation, antigen-retrieval, blocking conditions, etc. 
ON THE UNDERSTANDING OF THE BALANCE 
BETWEEN THE HOMO-AND HETERORECEPTOR 
COMPLEXES IN THE BRAIN 
Until now, most experimental work was focused on 
the study of GPCR receptor-receptor interactions as a 
phenomenon of binary interactions. In other words, it 
was only focused on the understanding of face-to-face 
protomer-protomer interactions and their allosteric 
receptor-receptor modulation and functional 
specificities (See www.gpcr-hetnet.com [64] for a 
complete list of all binary pairs of GPCR-GPCR 
interactions described so far). However, the 
phenomenon of GPCR oligomerization is a more 
complex and dynamic process, which involve many 
more parameters than the classical analysis of the 
interactions of the two involved protomers [86]. One 
emerging concept is that direct physical receptor-
receptor interactions in heteroreceptor complexes or 
altered balance with their homoreceptor complexes 
population can contribute to brain disease progression 
inter alias PD, depression, Schizophrenia, Alzheimer 
and addiction [61, 79]. When discussing the role of 
GPCR heteroreceptor complexes, it is of substantial 
interest to understand the balance/equilibrium between 
the corresponding homo- and heteroreceptor 
complexes in the plasma membrane of the cell (Figure 
1). It should be important to also consider a disruption 
or shift of the balance between corresponding receptor 
homomers and heteromer populations as a mechanism 
for disease development which therefore also 
represents a pharmacological target. 
 We have suggested that the introduction of in situ PLA 
(Figure 1) in combination with western blot, radioligand 
binding experiments and co-immunoprocipitation could 
open a new window to the understanding of the 
importance of the balance of the corresponding homo-
and heteroreceptor complexes [85]. The analysis of 
animal/human brain material with in situ PLA can 
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reveal if the relative abundance of specific homo-and 
heteroreceptor complexes in discrete brain regions is 
altered in brain diseases or under certain drug 
treatments, for instance, chronic L-dopa treatment in 
PD [61, 79].  
In this analysis, it is important also to determine the 
ratio between heteromers versus total number of the 
two participating receptor populations, using in addition 
to Western blots, receptor autoradiography and 
biochemical binding methods. The two latter methods 
show the densities and affinities of the two functional 
receptor populations. The relationship between these 
parameters will help to normalize the heteromer values 
for comparison between groups in addition to 
evaluating the potential changes in the total number of 
the two receptor populations [85].  
Certainly, we cannot compare or determine directly 
a balance between the homo- and heteroreceptor 
complexes populations in the same tissue using the in 
situ PLA approach, because of a technical limitation of 
the procedure itself. But the method could help us 
determine each population independently and compare 
their relative expression levels after an appropriate 
numerical analysis. Furthermore, it should help 
understand the effects that could be induced by 
agonist/antagonist treatments on the regulation of 
these homo-/heteroreceptor complexes in order to 
understand their potential roles as drug targets or as 
markers of brain disease progression. 
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Figure 1: On the understanding of the balance/equilibrium between GPCR homo- and heteroreceptor complexes population in 
the neuron membrane in the brain. (Top right) Schematic representation of the balance between different populations of homo 
and hetero-receptor complexes in a portion of the membrane cell. (Bottom) The panel represent an example of in situ PLA 
experiment performed in rat hippocampal free-floating sections using primary antibodies of different species directed to 
adenosine A2A and A2B receptors. The detected A2A-A2B heteroreceptor complexes are seen as red clusters indicated by 
arrows in each panel. Specific A2A-A2B clusters are visualized within discrete regions of the pyramidal cell layer of the 
Ammon´s horn and the molecular cell layer of the dentate gyros (ventral leaflet). The complex was also observed throughout the 
cortex and in the piriforme layer but were almost absent in the molecular cell layer of the dentate gyros (dorsal leaflet). The 
analysis of animal/human brain material with in situ PLA can reveal if the relative abundance of specific homo- heteroreceptor 
complexes in discrete brain regions is altered in brain diseases or under certain drug treatments. 
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